EDD Antibody (D-5): sc-515423
- EDD Antibody (D-5) is a mouse monoclonal IgG1 κ provided at 200 µg/ml
- raised against amino acids 1-300 mapping at the N-terminus of EDD of human origin
- recommended for detection of EDD of mouse, rat and human origin by WB, IP, IF and ELISA
- m-IgG Fc BP-HRP and m-IgG1 BP-HRP are the preferred secondary detection reagents for EDD Antibody (D-5) for WB applications. These reagents are now offered in bundles with EDD Antibody (D-5) (see ordering information below).
QUICK LINKS
SEE ALSO...
EDD Antibody (D-5) is a mouse monoclonal IgG1 antibody that detects EDD in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). EDD, or E3 identified by Differential Display, plays a crucial role in cellular regulation as a progestin-regulated gene isolated from T-47D human breast cancer cells. Anti-EDD antibody (D-5) recognizes a protein that functions as a potential E3 ubiquitin-protein ligase, which is essential for the ubiquitination process that tags proteins for degradation, thereby maintaining cellular homeostasis and regulating various signaling pathways. The presence of a HECT domain in the carboxy terminus of EDD is vital, as this domain facilitates the transfer of ubiquitin to substrate proteins, influencing processes such as cell cycle progression and apoptosis. EDD′s ability to bind ubiquitin and its homology to the Drosophila hyperplastic discs gene underscores its importance in tumor suppression and growth control, making EDD (D-5) antibody an invaluable tool for researchers studying cancer biology and cellular regulation.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
EDD Antibody (D-5) References:
- EDD mediates DNA damage-induced activation of CHK2. | Henderson, MJ., et al. 2006. J Biol Chem. 281: 39990-40000. PMID: 17074762
- The EDD E3 ubiquitin ligase ubiquitinates and up-regulates beta-catenin. | Hay-Koren, A., et al. 2011. Mol Biol Cell. 22: 399-411. PMID: 21118991
- EDD inhibits ATM-mediated phosphorylation of p53. | Ling, S. and Lin, WC. 2011. J Biol Chem. 286: 14972-82. PMID: 21383020
- Mammalian hyperplastic discs homolog EDD regulates miRNA-mediated gene silencing. | Su, H., et al. 2011. Mol Cell. 43: 97-109. PMID: 21726813
- Identification of phosphorylation sites on the E3 ubiquitin ligase UBR5/EDD. | Bethard, JR., et al. 2011. J Proteomics. 75: 603-9. PMID: 21924388
- EDD induces cell cycle arrest by increasing p53 levels. | Smits, VA. 2012. Cell Cycle. 11: 715-20. PMID: 22374670
- EDD enhances cell survival and cisplatin resistance and is a therapeutic target for epithelial ovarian cancer. | Bradley, A., et al. 2014. Carcinogenesis. 35: 1100-9. PMID: 24379240
- HIV-1 Vpr hijacks EDD-DYRK2-DDB1DCAF1 to disrupt centrosome homeostasis. | Hossain, D., et al. 2018. J Biol Chem. 293: 9448-9460. PMID: 29724823
- Prolactin-inducible EDD E3 ubiquitin ligase promotes TORC1 signalling, anti-apoptotic protein expression, and drug resistance in breast cancer cells. | MacDonald, TM., et al. 2019. Am J Cancer Res. 9: 1484-1503. PMID: 31392083
- Activated Wnt/β-Catenin signaling contributes to E3 ubiquitin ligase EDD-conferred docetaxel resistance in prostate cancer. | Bian, P., et al. 2020. Life Sci. 254: 116816. PMID: 31472148
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
EDD Antibody (D-5) | sc-515423 | 200 µg/ml | $316.00 | |||
EDD Antibody (D-5): m-IgG Fc BP-HRP Bundle | sc-541054 | 200 µg Ab; 10 µg BP | $354.00 | |||
EDD Antibody (D-5): m-IgG1 BP-HRP Bundle | sc-542553 | 200 µg Ab; 20 µg BP | $354.00 |